Clinical Trials California - Join Reasearch Studies and clinical trials in California

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... California

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine.

Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsor: Novartis Pharmaceuticals
Recruiting - verified September 2010
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified September 2010
HydroCoil Cerecyte Aneurysm Treatment Trial

Condition: Cerebral Aneursym
Interventions: Device: Micro Vention Hydrogel coil; Device: Non-hydrogel coils
Sponsors: University of Virginia; MicroVention Terumo
Recruiting - verified September 2010
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsor: Oxford BioMedica
Recruiting - verified September 2010
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: placebo; Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified September 2010
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With or Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: An Extension Trial to NN1250-3582

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: insulin aspart
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type II
Intervention: Drug: Insulin LISPRO
Sponsor: Halozyme Therapeutics
Recruiting - verified September 2010
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: An Extension Trial to NN1250-3579

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Condition: HCV Infection
Interventions: Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo
Sponsor: Gilead Sciences
Recruiting - verified August 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Insulin LISPRO
Sponsor: Halozyme Therapeutics
Recruiting - verified September 2010
Vitamin E for Extremely Preterm Infants

Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Intracranial Hemorrhages
Interventions: Drug: Vitamin E; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Not yet recruiting - verified July 2010
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsor: Innovative Medical
Not yet recruiting - verified September 2010
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or Nab-Paclitaxel

Conditions: Solid Tumors; Pancreatic Cancer; Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Dispensing Evaluation of a New Galyfilcon A Prototype and Avaira Lenses

Condition: Myopia
Interventions: Device: galyfilcon A prototype; Device: enfilcon A
Sponsor: Vistakon
Recruiting - verified August 2010
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Condition: Hemorrhage
Interventions: Biological: secondary hemostatic treatment; Device: Surgicel® Original
Sponsor: Nycomed
Not yet recruiting - verified August 2010
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis

Conditions: Hyperphosphatemia; High Phosphorus; Dialysis; Kidney Failure
Intervention: Drug: ferric citrate, calcium acetate, sevelamer carbonate, placebo
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified September 2010
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Condition: CLL
Intervention: Drug: Ofatumumab/HDMP
Sponsors: Chronic Lymphocytic Leukemia Research Consortium; GlaxoSmithKline
Recruiting - verified August 2010
CSP #556 - The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed VA Patients

Condition: Major Depressive Disorder
Interventions: Device: rTMS; Device: Sham Device
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified August 2010
Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

Condition: Menorrhagia
Interventions: Drug: Lysteda; Drug: Lysteda
Sponsor: Ferring Pharmaceuticals
Recruiting - verified August 2010
Grape Seed Extract and Postprandial Oxidation and Inflammation

Condition: Metabolic Syndrome
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Meganatural Gold®
Sponsor: University of California, Davis
Recruiting - verified August 2010
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Conditions: Facial Rhytides; Crow's Feet Lines; Glabellar Lines
Interventions: Other: botulinum toxin type A and Normal Saline (placebo); Biological: botulinum toxin type A; Drug: Normal Saline
Sponsor: Allergan
Not yet recruiting - verified August 2010
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Conditions: Lateral Canthus Rhytides; Crow's Feet Lines
Interventions: Biological: botulinum toxin type A; Drug: Normal Saline
Sponsor: Allergan
Not yet recruiting - verified August 2010
Comparing Manipulation, Rehabilitation and Combination of the Two in the Treatment of Knee Osteoarthritis

Condition: Osteoarthritis, Knee
Interventions: Other: Full Kinetic Chain Manipulative Therapy; Other: Full Kinetic Chain Rehabilitation; Other: Full Kinetic Chain Manipulative Therapy with Rehabilitation
Sponsors: Cleveland Chiropractic College; Durban University of Technology South Africa; Murdoch University
Not yet recruiting - verified August 2010
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration

Conditions: Wet Macular Degeneration; Macular Degeneration; Pigment Epithelium of Eye; Retinal Detachment
Interventions: Drug: ranibizumab; Drug: ranibizumab
Sponsors: Pacific Eye Associates; Genentech
Recruiting - verified August 2010
Safety Study to Investigate PSI-7977 in Combination With SOC in Treatment-Naïve HCV Patients With Chronic Hepatitis C Virus(HCV) Infection

Condition: Hepatitis C Virus
Interventions: Drug: PSI-7977 and SOC (PEG-IFN and RBV); Drug: PSI-7977
Sponsor: Pharmasset
Recruiting - verified August 2010
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); NIH Office of Rare Diseases Research
Recruiting - verified August 2010
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Conditions: Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin
Interventions: Procedure: 12Gy total skin electron beam therapy; Drug: Vorinostat
Sponsor: Stanford University
Not yet recruiting - verified August 2010
Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure

Condition: Heart Failure
Interventions: Drug: TRV120027; Drug: Placebo
Sponsor: Trevena Inc.
Not yet recruiting - verified August 2010
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Conditions: Lymphoblastic Leukemia, Acute; Lymphoblastic Leukemia, Acute, Childhood; Leukemia, Lymphoblastic, Acute, T Cell; Leukemia, Lymphoblastic, Acute
Interventions: Drug: EZN-3042; Drug: Cytarabine; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Enzon Pharmaceuticals, Inc.
Recruiting - verified August 2010
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: FBS0701; iron chelation
Sponsor: FerroKin BioSciences, Inc.
Recruiting - verified August 2010
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

Condition: Heart Transplant
Intervention: Drug: Pioglitazone
Sponsor: Stanford University
Recruiting - verified August 2010
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus
Intervention:
Sponsor: DexCom, Inc.
Recruiting - verified August 2010
Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload

Condition: Thalassemia
Intervention: Drug: Deferasirox
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Dose Response Study of Patients With Erythematous Rosacea

Condition: Erythematous (Type One) Rosacea
Interventions: Drug: V-101; Other: vehicle
Sponsors: Vicept Therapeutics, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified August 2010
A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

Conditions: HIV Infection; Gastrointestinal Symptoms
Interventions: Dietary Supplement: GanedenBC30, GBI-30, PTA-6086; Drug: Placebo
Sponsors: AIDS Healthcare Foundation; Ganeden Biotech, Inc.
Recruiting - verified August 2010
Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Non-responders

Conditions: Hepatitis C; Chronic
Interventions: Drug: DEB025 600 mg QD + SOC; Drug: DEB025 800 mg QD; Drug: placebo + SOC
Sponsor: Novartis
Recruiting - verified August 2010
SCAN Memory Program Evaluation Study

Condition: Dementia
Intervention: Behavioral: Dementia Care Management
Sponsors: VA Greater Los Angeles Healthcare System; University of California, Los Angeles
Recruiting - verified August 2010
The Effect of Sound Stimulation on Pure-tone Hearing Threshold

Condition: Sensorineural Hearing Loss
Intervention: Behavioral: Sound stimulation
Sponsor: Earlogic Korea, Inc.
Recruiting - verified August 2010
A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part II

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
Accuracy of Non-Invasive Blood Pressure Measurement in Adults

Conditions: Hypertension; Hypotension
Intervention:
Sponsor: Sotera Wireless, Inc.
Not yet recruiting - verified August 2010
Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Condition: Contraception
Interventions: Drug: Contraception; Drug: Contraception
Sponsor: Agile Therapeutics
Recruiting - verified August 2010
The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)

Condition: Normal Healthy Subjects
Interventions: Other: Hypothenar muscle activation--maximum, voluntary, isometric; Other: Thenar muscle activation--maximum, voluntary, isometric; Other: EDB muscle activation--maximum, voluntary, isometric
Sponsor: Loma Linda University
Not yet recruiting - verified August 2010
Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: Cinacalcet; Drug: Traditional Vitamin D Therapy
Sponsor: Amgen
Not yet recruiting - verified September 2010
Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation

Conditions: Lung Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer
Intervention: Procedure: Exhaled Breath Sampling
Sponsor: Stanford University
Recruiting - verified August 2010
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

Conditions: Cancer; Inflammation
Intervention:
Sponsor: University of California, Los Angeles
Recruiting - verified August 2010
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases.

Conditions: Autoimmune Diseases; Cancer
Intervention:
Sponsor: University of California, Los Angeles
Recruiting - verified August 2010
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: MP-376 (Levofloxacin solution for Inhalation); Drug: Placebo
Sponsor: Mpex Pharmaceuticals
Not yet recruiting - verified August 2010
Esmolol Infusion During Laminectomy: Effect on Quality of Recovery

Condition: Laminectomy
Intervention: Drug: Esmolol
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified March 2010
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder

Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: LuAA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study

Condition: Colorectal Cancer
Intervention: Procedure: Early urinary catheter removal
Sponsor: Stanford University
Recruiting - verified August 2010
Rituximab + Immune Globulin Intravenous (IVIG) for Desensitization

Condition: Kidney Transplantation
Intervention: Biological: Rituxan
Sponsors: Cedars-Sinai Medical Center; Genentech
Not yet recruiting - verified August 2010
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified September 2010
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

Conditions: Contraception; Female Contraception
Intervention: Drug: DR-102
Sponsor: Teva Women's Health
Recruiting - verified September 2010
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Condition: Smoking Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo
Sponsors: Nabi Biopharmaceuticals; GlaxoSmithKline
Recruiting - verified August 2010
Tinnitus Retraining Therapy Trial

Condition: Subjective Tinnitus
Interventions: Device: Conventional sound generator (SG); Device: Placebo sound generator (placebo SG); Behavioral: Standard of Care (SC); Behavioral: Directive Counseling (DC); Behavioral: Directive Counseling (DC)
Sponsors: Johns Hopkins Bloomberg School of Public Health; National Institute on Deafness and Other Communication Disorders (NIDCD); University of Alabama, Tuscaloosa; David Grant U.S. Air Force Medical Center; Wilford Hall Medical Center; United States Naval Medical Center, San Diego; United States Naval Medical Center, Portsmouth; National Naval Medical Center; Naval Hospital Camp Pendleton
Not yet recruiting - verified August 2010
Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents

Condition: Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Interventions: Behavioral: Cognitive-Behavioral Therapy; Behavioral: Wait-list
Sponsors: University of South Florida; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, Los Angeles; University of Miami
Recruiting - verified August 2010
Expectant Management Versus Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation And Absent or Reverse Diastolic Flow in the Umbilical Artery

Condition: Intrauterine Growth Retardation
Interventions: Procedure: selective laser photocoagulation of communicating vessels; Procedure: Expected Management
Sponsor: University of South Florida
Recruiting - verified February 2008
Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Blood draw
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

Condition: Birth Control
Interventions: Device: WC then FC2; Device: FC2 then WC
Sponsors: CONRAD; United States Agency for International Development (USAID); Program for Appropriate Technology in Health
Recruiting - verified August 2010
Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitor

Condition: Respiration
Intervention: Device: Non-Contact Respiratory Rate Monitor
Sponsor: Kai Medical, Inc.
Recruiting - verified August 2010
Dispensing Evaluation of 1-Day ACUVUE® DEFINE™ With LACREON™ for Light Eye Lenses

Condition: Myopia
Interventions: Device: 1-Day ACUVUE® DEFINE™ with LACREON™ for light eye lenses (ZBC); Device: 1-Day ACUVUE® DEFINE™ with LACREON™ for light eye lenses (PBC); Device: 1-Day ACUVUE® Moist
Sponsor: Vistakon
Recruiting - verified August 2010
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting - verified August 2010
Study to Assess Droxidopa in Treatment of Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Conditions: Orthostatic Hypotension; Parkinson's Disease
Intervention: Drug: Droxidopa
Sponsor: Chelsea Therapeutics
Recruiting - verified August 2010
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: Placebo; Drug: Mesalamine Granules 750 mg; Drug: Mesalamine Granules 1500 mg
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Condition: Rosacea
Interventions: Drug: CD07805/47 Gel; Drug: Vehicle Gel
Sponsor: Galderma
Recruiting - verified August 2010
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Condition: Solid Tumor Cancers
Interventions: Drug: veliparib; Drug: Temozolomide
Sponsor: Abbott
Recruiting - verified August 2010
Stress, Hormones, and Eating

Condition: Food Addiction
Intervention: Drug: Naltrexone
Sponsor: University of California, San Francisco
Recruiting - verified July 2010
Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children

Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Genetically-modified Neural Stem Cells (NSCs) and 5-Fluorocytosine in Treating Patients Undergoing Surgery For Recurrent High Grade Gliomas

Conditions: Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma
Interventions: Drug: flucytosine; Other: polymerase chain reaction; Other: immunohistochemistry staining method; Biological: gene therapy; Other: pharmacological study; Other: 3-Tesla magnetic resonance imaging; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Biological: E. coli CD-expressing genetically modified neural stem cells
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast and Liver Tumors

Conditions: Head and Neck Cancer; Liver Cancer; Breast Cancer; Gastric Cancer
Interventions: Drug: CUDC-101; Drug: CUDC-101
Sponsor: Curis, Inc.
Recruiting - verified August 2010
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Condition: Asthma
Interventions: Drug: 2.5 mcg tiotropium Respimat®; Drug: 5 mcg tiotropium Respimat®; Drug: 50 mcg salmeterol HFA MDI; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Not yet recruiting - verified August 2010
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Virtue® Male Sling Fixation Study

Condition: Stress Urinary Incontinence
Intervention: Device: Coloplast Virtue® Male Sling
Sponsor: Coloplast A/S
Recruiting - verified September 2010
Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae

Conditions: Chlamydia; Gonorrhea
Intervention:
Sponsor: Siemens Healthcare Diagnostics Inc
Recruiting - verified August 2010
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsor: ZIOPHARM
Recruiting - verified August 2010
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Condition: Advanced Solid Tumors
Intervention: Drug: ARQ 197 as monotherapy or in combination with other drug(s)
Sponsor: ArQule
Available - verified September 2010
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: FOLFIRI regimen; Drug: FOLFOX regimen; Drug: capecitabine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery
Sponsors: Walter Reed Army Medical Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Prasugrel Versus Placebo in Adult Sickle Cell Disease

Condition: Sickle Cell Anemia
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Monitoring Exhaled Propofol to Individualize General Anesthesia

Condition: General Anesthesia
Interventions: Drug: Propofol anesthesia; Drug: Sevoflurane anesthesia
Sponsor: University of California, San Francisco
Recruiting - verified August 2010
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Condition: Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate 20mg/1.0ml; Drug: Glatiramer Acetate 20mg/0.5ml
Sponsor: Teva Neuroscience, Inc.
Recruiting - verified August 2010
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Condition: Plaque Psoriasis
Interventions: Drug: Halobetasol Proprionate Lotion 0.05%; Drug: Halobetasol Proprionate Cream 0.05%
Sponsor: Therapeutics, Inc.
Recruiting - verified July 2010
Retrospective Chart Review of Subcutaneous IgG Use in Infants

Condition: Primary Immune Deficiency
Intervention: Biological: Subcutaneous IgG (SCIG)
Sponsor: CSL Behring
Recruiting - verified August 2010
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peginterferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
A Study in Second Line Non Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; ImClone LLC
Not yet recruiting - verified August 2010
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin aspart; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin detemir
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Dapagliflozin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified July 2010
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Condition: Hepatitis C, Chronic
Intervention:
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Condition: Asthma
Interventions: Drug: Vilanterol; Drug: Salmeterol Inhalation Powder; Drug: Placebo Inhalation Powder NDPI; Drug: Placebo Inhalation Powder Diskus
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Condition: Asthma
Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Furoate Inhalation Powder; Drug: Placebo Inhaltion Powder
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified August 2010
Efficacy and Safety Study of Lu AA21004 in Adults With Major Depressive Disorder

Condition: Depressive Disorder, Major
Interventions: Drug: Lu AA21004; Drug: Lu AA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis.

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Not yet recruiting - verified September 2010
Pilot Study of Raltegravir Lipodystrophy IISP

Condition: HIV Infection
Intervention: Drug: Raltegravir
Sponsors: Southern California Institute for Research and Education; Merck
Not yet recruiting - verified August 2010
A Study of Medication With or Without Psychotherapy for Complicated Grief

Conditions: Complicated Grief; Bereavement
Interventions: Drug: Citalopram; Behavioral: Complicated Grief Treatment; Other: Placebo
Sponsors: Columbia University; National Institute of Mental Health (NIMH); American Foundation for Suicide Prevention
Recruiting - verified August 2010
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: A-623; Drug: A-623; Drug: A-623; Other: Placebo Comparator
Sponsor: Anthera Pharmaceuticals
Recruiting - verified July 2010
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY 94-9027 Following Single and Multiple Dose Administration

Condition: Hemophilia A
Interventions: Drug: BAY94-9027; Drug: BAY94-9027
Sponsor: Bayer
Not yet recruiting - verified August 2010
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Conditions: Leukemia; Leukemia Acute Lymphoid Leukemia (ALL)
Intervention: Drug: Velcade
Sponsors: Stanford University; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
New Glucose Sensor Pediatric

Condition: Type 1 Diabetes Mellitus
Intervention:
Sponsor: Medtronic Diabetes
Recruiting - verified August 2010
The Perceived Impact of Children's Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

Condition: Cardiovascular Disease
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2010
A Study of LY900010 in Erectile Dysfunction

Condition: Erectile Dysfunction
Interventions: Drug: LY2452473; Drug: tadalafil; Drug: placebo (tadalafil); Drug: placebo (LY2452473)
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
A Study of GDC-0449 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: GDC-0449
Sponsor: Genentech
Available - verified August 2010
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

Condition: Healthy
Interventions: Drug: PF-03463275; Drug: PF-03463275; Drug: PF-03463275; Drug: Placebo; Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified September 2010
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel / Carboplatin; Drug: bavituximab
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified July 2010
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsor: Amgen
Recruiting - verified August 2010
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Condition: Breast Cancer
Interventions: Drug: CDX-011; Drug: "Investigator's Choice" chemotherapy
Sponsor: Celldex Therapeutics
Recruiting - verified August 2010
A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

Condition: Healthy Volunteer
Interventions: Drug: RO5024048; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 and Exemestane; Drug: Placebo and Exemestane
Sponsor: Merrimack Pharmaceuticals
Recruiting - verified August 2010
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Intraoperative Radiotherapy for Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Device: Intraoperative Radiotherapy
Sponsor: Hoag Memorial Hospital Presbyterian
Recruiting - verified August 2010
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified August 2010
Experimental Study to Validate the Modified Glucose Disposal Test

Condition: Diabetes
Intervention: Procedure: Insulin, glucose and staple isotopes
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Conditions: Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin; Lymphomas: Non-Hodgkin Peripheral T-Cell
Intervention: Drug: Nilotinib
Sponsors: Stanford University; Novartis
Recruiting - verified August 2010
Study of Silodosin to Facilitate Passage of Urinary Stones

Conditions: Ureteral Calculi; Kidney Stones; Urolithiasis
Interventions: Drug: silodosin; Drug: placebo
Sponsor: Watson Pharmaceuticals
Recruiting - verified August 2010
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine); Drug: TH-302; Drug: TH-302
Sponsors: Threshold Pharmaceuticals; PRA International
Recruiting - verified August 2010
Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)

Condition: Infertility
Interventions: Biological: SCH 900962 / Corifollitropin alfa / Org 36286; Biological: RecFSH / follitropin beta
Sponsor: Schering-Plough
Recruiting - verified August 2010
Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (Study P06031)

Condition: Infertility
Interventions: Biological: SCH 900962 / Corifollitropin alfa / Org 36286; Biological: RecFSH / follitropin beta
Sponsor: Schering-Plough
Recruiting - verified August 2010
A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsor: Healthpoint
Recruiting - verified August 2010
Temozolomide or MEK Inhibitor AZD6244 in Treating Patients With Metastatic Melanoma of the Eye

Condition: Intraocular Melanoma
Interventions: Drug: MEK inhibitor AZD6244; Drug: temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: Lurasidone HCl
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified August 2010
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: Lurasidone HCl
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified August 2010
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified September 2010
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsor: Eisai Inc.
Recruiting - verified July 2010
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: ELND002; Drug: Placebo
Sponsor: Elan Pharmaceuticals
Recruiting - verified September 2010
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

Condition: Parkinson Disease
Intervention:
Sponsors: Michael J. Fox Foundation for Parkinson's Research; Institute for Neurodegenerative Disorders
Recruiting - verified August 2010
Pregabalin Trial In HIV Neuropathic Pain

Conditions: HIV-1 Infection; Neuropathic Pain
Intervention: Drug: pregabalin (Lyrica)
Sponsor: Pfizer
Recruiting - verified August 2010
Epiduo Pediatric Acne Study

Condition: Acne
Interventions: Drug: adapalene and benzoyl peroxide; Drug: Topical Gel Vehicle
Sponsor: Galderma
Recruiting - verified August 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

Condition: Acute Gout
Interventions: Drug: ACZ885 (Canakinumab); Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat; Drug: Bevacizumab
Sponsor: Geron Corporation
Recruiting - verified August 2010
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Sitagliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib; Biological: Trastuzumab; Drug: Docetaxel; Drug: Paclitaxel; Drug: Vinorelbine
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: Docetaxel plus bavituximab or placebo
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified August 2010
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Condition: Chronic Hepatitis C Virus Genotype 1
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: Placebo; Drug: Peginterferon Alpha-2a; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Drug: Placebo; Biological: Ramucirumab DP
Sponsor: ImClone LLC
Recruiting - verified August 2010
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

Conditions: Benign Prostatic Hyperplasia; Enlarged Prostate
Interventions: Drug: Tadalafil; Drug: Placebo; Drug: Finasteride
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: CEP-33457; Drug: Placebo
Sponsor: Cephalon
Recruiting - verified August 2010
Safety and Efficacy of Recombinant Factor VIII (N8) in Male Children Previously Treated With Haemophilia A

Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified August 2010
A Study of GSK2118436 in Previously Treated BRAF Mutant Metastatic Melanoma

Conditions: Melanoma; BRAF Mutant Metastatic Melanoma
Intervention: Drug: GSK2118436
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: AZD2066; Drug: Placebo; Drug: Duloxetine
Sponsor: AstraZeneca
Recruiting - verified August 2010
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Condition: Intermittent Claudication
Interventions: Drug: Placebo; Drug: 375 mg CK-2017357; Drug: 750 mg CK-2017357
Sponsor: Cytokinetics
Recruiting - verified August 2010
A Study in Erectile Dysfunction

Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea

Condition: Irritable Bowel Syndrome
Intervention: Drug: JNJ-27018966
Sponsor: Furiex Pharmaceuticals, Inc
Recruiting - verified August 2010
A Long-Term, Open-Label, Study on Schizophrenia

Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Olanzapine; Drug: Aripiprazole; Drug: Risperidone; Drug: Quetiapine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders
Interventions: Drug: PF-04991532; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT

Condition: Coronary Artery Disease
Interventions: Other: Stenting plus OMT; Other: Standard of care
Sponsor: St. Jude Medical
Recruiting - verified August 2010
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

Conditions: HER2-negative Breast Cancer; Metastatic Disease
Interventions: Drug: Zoledronic acid; Drug: Zoledronic acid; Drug: Zoledronic acid
Sponsor: Novartis
Recruiting - verified August 2010
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension (0000-166)

Condition: Hypertension
Interventions: Drug: Placebo; Drug: Comparator: Amlodipine; Drug: Comparator: ISMN ER
Sponsor: Merck
Recruiting - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: LY2189265; Drug: Placebo (oral); Drug: Placebo (subcutaneous)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Study of BMS-790052 Add-On to Standard of Care in Treatment Naive Subjects

Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peg-interferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Condition: Ulcerative Colitis
Intervention: Drug: MMX mesalamine/ mesalazine
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Otelixizumab; Biological: Placebo
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation; GlaxoSmithKline
Recruiting - verified May 2010
A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors

Condition: Nonarteritic Anterior Ischemic Optic Neuropathy
Intervention:
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
First in Human Study to Determine the Safety, Tolerability and Preliminary Effectiveness of MDX-1338 (BMS 936564) in Subjects With Acute Myelogenous Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: MDX-1338/BMS-936564 (Anti-CXCR4); Drug: MDX-1338/BMS-936564 (Anti-CXCR4)
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified July 2010
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Available - verified August 2010
A Study to Assess Safety and Efficacy of Odanacatib (MK0822) in Men With Osteoporosis (0822-053)

Condition: Osteoporosis
Interventions: Drug: odanacatib; Drug: Comparator: Placebo; Dietary Supplement: Comparator: Vitamin D3; Dietary Supplement: Comparator: Calcium carbonate
Sponsor: Merck
Recruiting - verified August 2010
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium 2.5 mcg; Drug: tiotropium 5 mcg; Drug: Tiotropium 18 mcg; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies

Condition: Pelvic Organ Prolapse
Interventions: Procedure: Robotic Assisted Laparoscopic ASC; Procedure: Laparoscopic Abdominal Sacrocolpopexy
Sponsors: Loyola University; National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Recruiting - verified August 2010
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Once-daily QVA149; Drug: once-daily NVA237; Drug: once-daily tiotropium
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Conditions: Sickle Cell Disease; Vaso-occlusive Crisis; Pain Crisis
Interventions: Drug: GMI-1070; Drug: Placebo
Sponsor: GlycoMimetics Incorporated
Recruiting - verified August 2010
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Recently Released From Jail

Condition: Schizophrenia
Interventions: Drug: olanzapine; Drug: paliperidone; Drug: quetiapine; Drug: paliperidone palmitate; Drug: haloperidole; Drug: aripiprazole; Drug: risperidone; Drug: perphenazine
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified August 2010
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Condition: Pelvic Pain Associated With Refractory Endometriosis
Interventions: Drug: BGS649; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified May 2010
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Tumors of the Brain

Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
Sponsor: University of California, San Francisco
Recruiting - verified August 2010
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Condition: Chronic Pain
Intervention: Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab-DM1; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified August 2010
Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

Condition: Chlamydia Trachomatis
Interventions: Drug: doxycyline hyclate tablet; Drug: Vibramycin (doxycyline hyclate) capsule
Sponsor: Warner Chilcott
Recruiting - verified August 2010
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Collaborative Study Group (CSG)
Recruiting - verified August 2010
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Condition: Phenylketonuria
Interventions: Drug: Sapropterin dihydrochloride; Drug: Placebo
Sponsor: BioMarin Pharmaceutical
Recruiting - verified August 2010
How Lidocaine Affects Outcomes In Orthopedic Surgery Patients

Conditions: Orthopedic; Surgery; Elderly
Intervention: Drug: Lidocaine
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified March 2010
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Condition: Progressive Supranuclear Palsy
Interventions: Drug: Davunetide; Drug: Placebo
Sponsor: Allon Therapeutics
Not yet recruiting - verified August 2010
Medical Review: Hand Surgery After Local Block Versus Non-block

Condition: Carpal Tunnel Syndrome
Intervention:
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified February 2010
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Conditions: Lung Neoplasms; Carcinoma; Cancer of the Lung; Non-Small-Cell Lung Carcinoma
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: Vinorelbine
Sponsors: Bristol-Myers Squibb; Eli Lilly and Company
Recruiting - verified July 2010
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Not yet recruiting - verified August 2010
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: Pertuzumab; Drug: Erlotinib
Sponsors: Stanford University; Genentech
Recruiting - verified August 2010
Insulin Lispro 6 Days Versus Aspart 6 Days in Pump Use

Condition: Diabetes Mellitus, Type 1
Interventions: Other: Insulin Lispro 2 day reservoir in-use; Other: Insulin Lispro 6 Day reservoir in-use; Other: Insulin aspart 6 day reservoir in-use
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Condition: Dyslipidemia
Interventions: Drug: LY2484595; Drug: Atorvastatin; Drug: Simvastatin; Drug: Rosuvastatin; Drug: Placebo for LY2484595; Drug: Placebo for Statins
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Other: Saline; Drug: Docetaxel; Drug: LY2181308
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

Condition: Hemophilia A With Inhibitors
Interventions: Drug: recombinant activated factor VII; Drug: recombinant activated factor VII
Sponsor: Fondazione Ospedale Maggiore Policlinico Milano
Not yet recruiting - verified August 2010
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Conditions: Breast Cancer; Melanoma
Intervention: Drug: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
A Study of the Safety and Tolerability of MEDI-570 (Experimental Drug) in Systemic Lupus Erythematosus

Condition: SLE
Interventions: Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570
Sponsors: MedImmune LLC; AstraZeneca
Recruiting - verified August 2010
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine Dimesylate; Drug: Atomoxetine Hydrochloride
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
A Study in Patients With Moderate to Severe Psoriasis

Condition: Psoriasis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Sponsor: Cephalon
Recruiting - verified August 2010
A Twenty-eight Week Safety, Extension Study of Flibanserin to Treat Premenopausal and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Intervention: Drug: flibanserin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsor: Andromeda Biotech Ltd.
Recruiting - verified August 2010
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

Condition: Osteoarthritis
Interventions: Drug: PH-797804; Drug: Placebo; Drug: Placebo; Drug: PH-797804; Drug: Naproxen; Drug: Naproxen + PH-797804; Drug: Naproxen + PH-797804; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified August 2010
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: eribulin mesylate + erlotinib; Drug: eribulin mesylate + erlotinib
Sponsor: Eisai Inc.
Recruiting - verified May 2010
Femoral Micropuncture or Routine Introducer Study

Condition: Complications
Interventions: Device: Micropuncture needle set; Device: Standard gauge-18 needle set
Sponsor: Cook
Recruiting - verified August 2010
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsor: CSL Behring
Recruiting - verified August 2010
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
24-Week Efficacy & Safety Study of Mesafem Capsules in the Treatment of VMS

Conditions: Vasomotor Symptoms; Menopause
Intervention: Drug: Mesafem Capsules
Sponsor: Noven Pharmaceuticals
Recruiting - verified August 2010
An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

Condition: Osteopenia
Interventions: Drug: Placebo; Drug: AMG 167
Sponsor: Amgen
Recruiting - verified August 2010
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Conditions: Acute Coronary Syndrome; Gout
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Asimadoline; Drug: Placebo
Sponsors: Tioga Pharmaceuticals; RTI Health Solutions
Recruiting - verified August 2010
A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial)

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

Conditions: Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
Interventions: Drug: Vancomycin; Drug: Vancomycin; Drug: Daptomycin 7-14 days moderate renal impairment; Drug: Daptomycin 7 - 14 days severe renal impairment, hemodialysis; Drug: Daptomycin 7 - 14 days severe renal impairment no hemodialysis; Drug: Daptomycin 14 - 42 days, moderate renal impairment; Drug: Daptomycin 14 - 42 days, severe renal impairment on hemodialysis; Drug: Daptomycin 14 - 42 days severe renal impairment, no hemodialysis
Sponsor: Cubist Pharmaceuticals
Recruiting - verified August 2010
Gastrointestinal Hormonal Regulation of Obesity

Condition: Obesity
Interventions: Dietary Supplement: Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass; Dietary Supplement: Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate; Dietary Supplement: Very high protein diet group based on 1.4 gram of protein per pound of subject's lean body mass: 35% protein and 35% carbohydrate.
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified August 2010
ACT-293987 in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsor: Actelion
Recruiting - verified August 2010
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

Condition: Major Depressive Disorder
Interventions: Drug: CP-601,927; Other: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitaliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 300 mg; Drug: sitaliptin 100 mg; Drug: Placebo/ sitagliptin 100 mg; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: placebo; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
A Study in Men With Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: LY500307; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Condition: Diagnostic Imaging
Interventions: Drug: PET tracer (BAY94-9392); Drug: PET tracer (BAY94-9392)
Sponsor: Bayer
Recruiting - verified August 2010
Clinical Evaluation of a 1-Piece Intraocular Lens

Condition: Cataract
Interventions: Device: Tecnis ZCB00 IOL; Device: Toric Intraocular lens
Sponsor: Abbott Medical Optics
Recruiting - verified August 2010
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Drug: Capecitabine + Perifosine or Placebo
Sponsor: Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified August 2010
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension

Conditions: Diabetes Mellitus, Type 2; Hypertension
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 12.5mg HCTZ
Sponsor: Pfizer
Recruiting - verified August 2010
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Condition: HIV Infections
Interventions: Biological: rAd35 Env A; Biological: rAd5 Env A; Biological: rAd5 Env B
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified August 2010
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Condition: Parkinson's Disease
Intervention: Drug: IPX066
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified August 2010
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

Conditions: Keratoconus; Ectasia; Degeneration
Intervention:
Sponsor: Innovative Medical
Recruiting - verified September 2010
Mindfulness Based Relapse Prevention for Stimulant Users

Condition: Stimulant Dependence
Interventions: Behavioral: Mindfulness Based Relapse Prevention; Behavioral: Health Education
Sponsor: University of California, Los Angeles
Recruiting - verified March 2010
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Condition: Asthma
Interventions: Drug: BI 671800; Drug: BI 671800; Drug: BI 671800; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
PF-00489791 For The Treatment Of Raynaud's

Conditions: Raynaud's Disease; Peripheral Vascular Disease
Interventions: Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791
Sponsor: Pfizer
Recruiting - verified September 2010
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

Conditions: Major Depressive Disorder; Dysthymia; Depression Not Otherwise Specified; Borderline Personality Disorder
Interventions: Drug: Lithium Carbonate; Drug: Placebo; Drug: Citalopram
Sponsor: Columbia Northwest Pharmaceuticals
Recruiting - verified August 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy
Interventions: Drug: Eslicarbazepine acetate 1600 mg; Drug: Eslicarbazepine acetate 1200 mg
Sponsor: Sepracor, Inc.
Recruiting - verified August 2010
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Condition: Leukemia
Intervention: Drug: Bendamustine
Sponsor: Cephalon
Recruiting - verified August 2010
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Intervention: Drug: ADP receptor inhibitors
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Condition: Spondolyarthropathies
Interventions: Biological: Certolizumab pegol; Biological: Certolizumab pegol; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Placebo; Drug: Glimepiride
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Condition: Arthritis, Psoriatic
Interventions: Biological: CZP 200mg Q2W; Biological: CZP 400mg Q4W; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified August 2010
A Study in Schizophrenia Patients

Condition: Schizophrenia
Interventions: Drug: Risperidone; Drug: Placebo; Drug: LY2140023
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Study to Investigate CAL-101 in Combination With Bendamustine and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab
Sponsor: Calistoga Pharmaceuticals, Inc.
Recruiting - verified August 2010
Study for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis

Conditions: Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: Levofloxacin; Drug: ACHN-490 Injection; Drug: ACHN-490 Injection
Sponsor: Achaogen, Inc.
Recruiting - verified August 2010
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Genentech; Abbott
Recruiting - verified August 2010
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: BMS-908662; Drug: BMS-908662; Drug: Cetuximab
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2010
Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Investigation in Pregnancy Associate Cardiomyopathy

Conditions: Cardiomyopathy; Pregnancy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified August 2010
LUX-Lung 5: BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: Investigator´s choice of chemotherapy
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis

Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Device: autoinjector; Device: pre-filled syringe
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
OTO-104 for Meniere's Disease

Condition: Meniere's Disease
Interventions: Drug: OTO-104 (steroid) 3 mg; Drug: Placebo; Drug: OTO-104 (steroid) 12 mg
Sponsor: Otonomy, Inc.
Recruiting - verified June 2010
Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsors: BiPar Sciences; Sanofi-Aventis
Recruiting - verified August 2010
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 300 mg; Drug: Canagliflozin 300 mg; Drug: Placebo/sitagliptin 100 mg; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Drug: laquinimod 0.5mg + standard of care; Drug: laquinimod 1mg + standard of care; Other: placebo + standard of care
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Interventions: Drug: Placebo; Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsor: Shire Pharmaceutical Development
Not yet recruiting - verified August 2010
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: BMS-708163; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection

Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Recruiting - verified August 2010
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified August 2010
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

Condition: Joint Damage
Interventions: Drug: Febuxostat; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Safety and Efficacy of 12 Weeks of Varenicline for Smoking Cessation in Smokers With Depression

Conditions: Smoking Cessation; Depression
Interventions: Drug: varenicline; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
A Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC)

Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; Teva Pharmaceuticals USA
Recruiting - verified August 2010
Febuxostat Versus Allopurinol or Placebo in Subjects With Hyperuricosuria and Calcium Oxalate Stones

Conditions: Hyperuricosuria; Kidney Stones
Interventions: Drug: Febuxostat; Drug: Allopurinol; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis Who Have Prior Exposure to Anti TNF Agents

Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Condition: Acute Coronary Syndrome
Interventions: Drug: eptifibatide; Drug: unfractionated heparin placebo; Drug: unfractionated heparin; Drug: otamixaban (XRP0673); Drug: eptifibatide placebo; Drug: otamixaban placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Conditions: Brain and Central Nervous System Tumors; Malignant Paraganglioma
Interventions: Drug: temozolomide; Drug: vorinostat; Genetic: DNA methylation analysis; Genetic: western blotting; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
4965 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
nEw3 Post-approval Study

Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
4968 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Conditions: Alzheimer's Disease; Central Nervous System Diseases; Cognition
Interventions: Drug: EVP-6124; Drug: Placebo
Sponsors: EnVivo Pharmaceuticals, Inc.; INC Research Limited
Recruiting - verified August 2010
Vaccine Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified August 2010
Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified November 2009
Empiric Therapy of Mucopurulent Cervicitis (MPC)

Conditions: C. Trachomatis; Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Cefixime; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Athena Pelvic Muscle Trainer - DUETS Trial

Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified September 2010
Treatment Interruption of Natalizumab

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Recruiting - verified August 2010
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsor: Argos Therapeutics
Recruiting - verified August 2010
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Condition: Intra-abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsor: Bayer
Recruiting - verified August 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified August 2010
Study of Multiple Doses and Regimens of XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified August 2010
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Condition: Neoplasm
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Regorafenib (BAY73-4506)
Sponsor: Bayer
Recruiting - verified August 2010
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA); Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
A Randomized Control Trial Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

Condition: Diabetes Mellitus
Intervention: Drug: VIAject U-100 Insulin
Sponsors: Stanford University; Biodel; Barbara Davis Center for Childhood Diabetes
Not yet recruiting - verified August 2010
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Condition: Lesch-Nyhan Disease
Intervention: Drug: Ecopipam
Sponsor: Psyadon Pharma
Recruiting - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
S-ICD® System IDE Clinical Study

Condition: Tachycardia, Ventricular
Intervention: Device: S-ICD System
Sponsor: Cameron Health, Inc.
Recruiting - verified August 2010
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Daiichi Sankyo Inc.
Recruiting - verified September 2010
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Condition: Cytomegalovirus
Interventions: Drug: AIC246; Drug: AIC246; Drug: AIC246; Other: Placebo
Sponsors: AiCuris GmbH & Co.KG; Quintiles
Recruiting - verified August 2010
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

Conditions: Chronic Optic Nerve Atrophy; Non-Arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses
Sponsor: Quark Pharmaceuticals
Recruiting - verified August 2010
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency
Interventions: Drug: Canagliflozin 300 mg; Drug: Placebo; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Condition: Ankylosing Spondylitis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Evaluation of SAR153191(REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191(REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: ATN-103; Drug: ATN-103; Drug: ATN-103
Sponsor: Wyeth
Recruiting - verified August 2010
A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Conditions: Cystitis, Interstitial; Urologic Diseases; Urinary Bladder Diseases; Cystitis
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Condition: Cardiovascular Disease
Interventions: Drug: dalcetrapib; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Conditions: Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 6
Intervention:
Sponsors: University of Florida; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Conditions: Bladder Cancer; Skin Cancers; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Intervention:
Sponsors: Stanford University; National Institutes of Health (NIH); Providence Foundation
Recruiting - verified August 2010
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550; Drug: Atorvastatin; Drug: CP-690,550; Drug: Atorvastatin Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Safety and Efficacy of Cariprazine for Bipolar I Disorder

Conditions: Mania; Bipolar I Disorder
Interventions: Drug: Cariprazine low dose; Drug: Cariprazine high dose; Drug: Placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified August 2010
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Nebivolol in Patients With Systolic Stage 2 Hypertension

Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma

Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified August 2010
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Condition: Hepatitis C, Chronic
Intervention: Drug: Telaprevir/standard treatment
Sponsors: Tibotec Pharmaceuticals, Ireland; Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

Condition: HIV Infections
Interventions: Biological: HIV-1 DNA plasmid vaccine; Biological: HIV-1 recombinant Ad5 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
Sponsor: Reata Pharmaceuticals, Inc.
Recruiting - verified August 2010
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

Condition: Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Neuroscience, Inc.; H. Lundbeck A/S
Recruiting - verified August 2010
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo; Drug: Standard of Care
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor: Bayer
Recruiting - verified August 2010
Cell Phone Reminders Intervention

Conditions: HAART Non-Adherence; HIV; HIV Infections
Intervention: Behavioral: Cell Phone Intervention
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
A Study for Patients With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Healthier Living Canada

Conditions: Asthma; Chronic Disease
Intervention: Behavioral: Chronic Disease Self-Management Online Workshop
Sponsors: Stanford University; Alberta Health Services; National Council on Aging
Recruiting - verified August 2010
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsor: Bristol-Myers Squibb
Recruiting - verified September 2010
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers

Conditions: Breast Cancer; Ductal Breast Carcinoma in Situ; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Other: educational intervention; Procedure: quality-of-life assessment; Other: Questionnaire Administration; Other: psychosocial support for caregiver; Procedure: assessment of therapy complications; Other: informational intervention
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Figitumumab; Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: Conatumumab
Sponsor: Foundation for the National Institutes of Health
Recruiting - verified August 2010
A Study is to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered Tapentadol ER at Dosages of 100 to 250 mg Twice Daily Compared With Placebo in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified August 2010
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

Conditions: Leukemia Lymphoblastic, Acute; Acute Myeloid Leukemia; Neoplasm Recurrent
Interventions: Drug: Clofarabine; Radiation: Total Body Irradiation; Other: Stem Cell Infusion; Drug: Cyclosporins; Drug: Mycophenolate mofetil
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress

Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified September 2010
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: FBS0701
Sponsor: FerroKin BioSciences, Inc.
Recruiting - verified December 2009
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: STA-9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified August 2010
A Study of YM155 Plus Docetaxel in Subjects With HER2 Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified September 2010
FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

Condition: Ankle Sprain
Interventions: Drug: FS-67; Other: Placebo
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
Recruiting - verified August 2010
Efficacy and Safety of EN3324 in Subjects With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified August 2010
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Spinal Cord Stimulation With Precision® SCS System Versus Reoperation for Failed Back Surgery Syndrome

Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsor: Boston Scientific Corporation
Recruiting - verified August 2010
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Imatinib mesylate; Drug: Imatinib mesylate; Drug: Imatinib mesylate
Sponsors: Sarcoma Alliance for Research through Collaboration; Novartis Pharmaceuticals
Recruiting - verified August 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified August 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib; Drug: etoposide
Sponsor: OSI Pharmaceuticals
Recruiting - verified June 2010
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

Condition: Breast Cancer
Intervention:
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Acute Flu-Like Illness

Condition: Infection
Interventions: Drug: Ibuprofen; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified August 2010
A Study of AMNN107 Against Dacarbazine (DTIC) in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Interventions: Drug: nilotinib (AMN107); Drug: decarbazine (DTIC)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Condition: Stage III Melanoma, Stage IV Melanoma
Intervention: Biological: MKC1106-MT
Sponsor: Mannkind Corporation
Not yet recruiting - verified August 2010
XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.

Condition: Spondylolisthesis
Intervention:
Sponsor: NuVasive
Recruiting - verified August 2010
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine, Bosutinib
Sponsors: University of California, San Francisco; University of Utah
Recruiting - verified August 2010
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab
Sponsors: Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified August 2010
A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared to Best Supportive Care in Patients With Multicentric Castleman's Disease

Condition: Castleman's Disease
Interventions: Other: Placebo; Drug: CNTO 328
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation

Condition: Parkinson Disease
Intervention:
Sponsors: Department of Veterans Affairs; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis
Interventions: Drug: Azelastine hydrochloride nasal spray 0.15%; Drug: Azelastine hydrochloride nasal spray 0.10%; Drug: Placebo
Sponsor: Meda Pharmaceuticals
Recruiting - verified August 2010
Intravenous BI 6727 in 2nd Line Treatment of Urothelial Cancer

Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Condition: Hepatic Insufficiency
Intervention: Drug: BMS-650032
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID)for Knee Pain Due to Osteoarthritis

Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Adolescent Fibromyalgia Study

Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified August 2010
Pregabalin In Adolescent Patients With Fibromyalgia

Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsor: Pfizer
Not yet recruiting - verified August 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified June 2010
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection

Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: Tazarotene Foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified August 2010
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2010
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study With RO4917523 in Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: Placebo; Drug: RO4917523; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
MLN1202 in Treating Patients With Bone Metastases

Conditions: Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: anti-CCR2 monoclonal antibody MLN1202; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified August 2010
Phase III Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Condition: Alzheimer Disease
Intervention: Drug: Florbetaben (BAY94-9172)
Sponsor: Bayer
Recruiting - verified August 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
Sponsor: Seattle Genetics, Inc.
Recruiting - verified August 2010
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Study of XL147 in Advanced or Recurrent Endometrial Cancer

Conditions: Endometrial Cancer; Endometrial Neoplasms
Intervention: Drug: XL147
Sponsor: Exelixis
Recruiting - verified August 2010
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Condition: Melanoma
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified August 2010
Managerial Database II

Condition: HIV
Intervention: Other: Observation
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2010
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Condition: Advanced Pancreatic Cancer
Intervention: Drug: Tarceva, Gemcitabine, Nab-Paclitaxel
Sponsors: OSI Pharmaceuticals; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified April 2010
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: cixutumumab; Drug: sorafenib tosylate; Other: laboratory biomarker analysis
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis

Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Other: SPECT-CT imaging
Sponsor: University of California, San Francisco
Recruiting - verified November 2009
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: Paliperidone PR; Drug: Aripiprazole
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma

Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified August 2010
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241
Sponsor: Pfizer
Recruiting - verified August 2010
Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery

Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug: Vehicle
Sponsors: Hologic, Inc.; PRA International
Recruiting - verified August 2010
Gene Therapy for Painful Diabetic Neuropathy

Condition: Painful Diabetic Neuropathy
Intervention: Genetic: VM202
Sponsor: ViroMed Co., Ltd.
Recruiting - verified August 2010
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: PEG-rIL-29; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: ZymoGenetics; Bristol-Myers Squibb
Recruiting - verified September 2010
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified August 2010
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Allopurinol Combination Study

Condition: Gout
Interventions: Drug: RDEA594; Drug: Placebo; Drug: Allopurinol
Sponsor: Ardea Biosciences, Inc.
Recruiting - verified August 2010
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate); Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Sponsor: Raptor Pharmaceutical Corp.
Recruiting - verified August 2010
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsor: Allos Therapeutics
Recruiting - verified August 2010
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified September 2010
TAXUS Libertē Post Approval Study

Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified September 2010
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Subjects With Essential Hypertension

Condition: Essential Hypertension
Interventions: Drug: Azilsartan medoxomil and chlorthalidone; Drug: Olmesartan medoxomil and hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

Conditions: Parkinson's Disease; Essential Tremor; Dystonia
Intervention: Device: Activa RC
Sponsor: MedtronicNeuro
Recruiting - verified August 2010
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

Condition: Arrhythmia Prophylaxis
Interventions: Drug: Celivarone (SSR149744); Drug: amiodarone; Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline; Drug: placebo
Sponsors: University of South Florida; National Ataxia Foundation; Bob Allison Ataxia Research Center (BAARC); Pfizer
Recruiting - verified July 2010
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

Conditions: HIV Infections; H1N1 Influenza Virus
Intervention: Biological: Influenza A (H1N1) monovalent vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified August 2010
Genotype Information and Functional Testing Study

Condition: Coronary Artery Disease
Intervention:
Sponsors: Scripps Health; Bristol-Myers Squibb; Sanofi-Aventis; Accumetrics, Inc.
Recruiting - verified August 2010
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified August 2010
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified September 2010
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Sepracor, Inc.
Recruiting - verified August 2010
A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion

Conditions: Tibiotalar Arthrodesis; Subtalar Arthrodesis; Calcaneocuboid Arthrodesis; Talonavicular Arthrodesis; Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular); Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)
Intervention: Biological: Trinity Evolution
Sponsor: Orthofix Inc.
Recruiting - verified August 2010
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

Conditions: Parkinsons Disease With Dementia; Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Intervention: Drug: Rivastigmine Patch 9.5 cm2
Sponsors: University of California, San Francisco; Novartis
Recruiting - verified September 2009
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified August 2010
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

Condition: Idiopathic Parkinson's Disease
Interventions: Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin; Procedure: Sham Surgery
Sponsor: Ceregene
Recruiting - verified August 2010
A Pilot Study for Collection of Anti-Influenza A H1N1 (Swine Flu) Plasma

Conditions: H1N1 Influenza; Swine Flu
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2009
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Oxepa; Dietary Supplement: Jevity 1.5; Dietary Supplement: Jevity 1.0
Sponsors: Massachusetts General Hospital; Muscular Dystrophy Association
Recruiting - verified August 2010
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin (fixed dose); Drug: ribavirin (weight-based dose)
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified August 2010
Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: Hedgehog antagonist GDC-0449; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Conditions: Solid Tumor; Kidney Neoplasms; Advanced Renal Cell Carcinoma
Interventions: Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified August 2010
Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543 and NN7008-3545

Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Condition: Breast Cancer
Interventions: Drug: BIIB021; Drug: BIIB021; Drug: exemestane (Aromasin)
Sponsor: Biogen Idec
Recruiting - verified August 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified August 2010
Treatment Failure of Chlamydial Infection in Females in Youth Correctional Facilities

Condition: C. Trachomatis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Condition: Hemophilia B
Intervention: Genetic: Gene Transfer
Sponsors: St. Jude Children's Research Hospital; Stanford University; Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified August 2010
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Condition: Multiple System Atrophy
Interventions: Drug: rasagiline mesylate; Other: placebo
Sponsors: Teva Pharmaceutical Industries; H. Lundbeck A/S
Recruiting - verified August 2010
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Sitagliptin
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: Chemotherapy + figitumumab; Drug: Chemotherapy
Sponsor: Pfizer
Recruiting - verified August 2010
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Subjects With PHPT Unable to Undergo Parathyroidectomy

Condition: Hyperparathyroidism, Primary
Interventions: Drug: cinacalcet HCl; Drug: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified August 2010
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Conditions: HIV Infections; Treatment Experienced
Interventions: Biological: DNA + HIV-rAd5 vaccine; Drug: ART intensification (raltegravir); Drug: ART intensification (maraviroc)
Sponsors: Northwestern University; ORVACS (Objectif Recherche Vaccin SIDA); National Institute of Allergy and Infectious Diseases (NIAID); Pfizer; Merck
Recruiting - verified August 2010
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Condition: Non-small Cell Lung Cancer
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified August 2010
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

Condition: Acute On Chronic Hepatitis
Interventions: Device: Extracorporeal Liver Assist Device (ELAD); Other: Standard of care
Sponsor: Vital Therapies, Inc.
Recruiting - verified May 2010
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: JNJ-28431754; Drug: glimepiride
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Conditions: Schizophrenia; Central Nervous System Diseases; Cognition
Interventions: Drug: EVP-6124; Drug: Placebo
Sponsors: EnVivo Pharmaceuticals, Inc.; INC Research Limited
Recruiting - verified August 2010
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery using the Novalis Tx
Sponsor: San Diego Radiosurgery
Recruiting - verified August 2010
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Conditions: Colorectal Cancer; Neoplasms, Colorectal
Interventions: Drug: CS7017; Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Erlotinib; Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified August 2010
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsor: Celgene Corporation
Recruiting - verified August 2010
A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
LIP-01 in Hypercholesterolemia

Condition: Hypercholesterolemia
Intervention: Dietary Supplement: LIP-01
Sponsor: Afexa Life Sciences Inc
Recruiting - verified August 2010
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified September 2010
Implantable Systems Performance Registry

Conditions: Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Nerve Stimulation
Intervention: Device: Various
Sponsor: MedtronicNeuro
Recruiting - verified August 2010
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study in Relapse Prevention of Treatment-resistant Depression

Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents; Drug: Placebo Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified July 2010
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder

Condition: Depression
Intervention: Device: Transcranial Magnetic Stimulation
Sponsor: University of California, Los Angeles
Recruiting - verified July 2010
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified August 2010
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

Condition: Hematologic Malignancies
Interventions: Drug: PF-04449913; Drug: dasatinib
Sponsor: Pfizer
Recruiting - verified August 2010
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: AMG 827 70 mg; Drug: AMG 827 140 mg; Drug: AMG 827 210 mg
Sponsor: Amgen
Recruiting - verified September 2010
BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified August 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes

Condition: Diabetes Mellitus
Intervention: Drug: Generex Oral-lyn™
Sponsor: Generex Biotechnology Corp.
Available - verified August 2010
Japanese Bridging Study Conducted in the United States

Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified May 2010
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified August 2010
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Condition: Cancer
Intervention: Drug: dalteparin
Sponsor: Eisai Inc.
Recruiting - verified August 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified September 2010
PF-02341066 in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Conditions: Adenoma; Prolactinoma
Intervention: Drug: Lapatinib
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified September 2010
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Condition: Relapsed Acute Myelogenous Leukemia
Interventions: Drug: clofarabine; Drug: etoposide; Drug: cyclophosphamide; Drug: filgrastim; Drug: cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Study of XL184 in Adults With Advanced Malignancies

Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Dinaciclib in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: dinaciclib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified August 2010
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

Conditions: Neoplasms; Melanoma; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: PF-04217329; Drug: PF-04217329 + latanoprost
Sponsor: Pfizer
Recruiting - verified August 2010
Atkins Diet and Prostate Cancer Clinical Trial

Condition: Prostate Cancer
Intervention: Behavioral: Atkins Diet
Sponsors: Duke University; VA Greater Los Angeles Healthcare System; Durham VA Medical Center; University of California, Los Angeles; Santa Monica UCLA Medical Center
Recruiting - verified August 2010
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified August 2010
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified August 2010
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: PF-03758309
Sponsor: Pfizer
Recruiting - verified August 2010
Abatacept Versus Adalimumab Head-to-Head

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Not Responded to Treatment

Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Treatment of West Nile Virus With MGAWN1

Conditions: West Nile Neuroinvasive Disease; West Nile Virus Infection; Encephalitis; Meningitis; Acute Flaccid Paralysis; West Nile Fever
Interventions: Biological: MGAWN1; Biological: Placebo - normal saline
Sponsors: MacroGenics; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Condition: Cancer
Intervention: Drug: PF-04691502
Sponsor: Pfizer
Recruiting - verified August 2010
Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder

Condition: Major Depressive Disorder
Interventions: Device: Brainsway H-Coil Deep TMS System; Device: Brainsway H-Coil Deep TMS System (Sham treatment)
Sponsor: Brainsway
Recruiting - verified August 2010
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified August 2010
A Multicenter Study to Evaluate the Effects of DR-105 on Bone Mineral Density in Adolescent Females

Condition: Bone Mineral Density
Interventions: Drug: DR-105; Drug: Lessina®; Other: Control Group
Sponsor: Duramed Research
Recruiting - verified August 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified July 2010
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified September 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: bone scan; Procedure: scintigraphy; Radiation: calcium-41 chloride aqueous solution; Radiation: calcium-46 chloride aqueous solution
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified August 2010
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Study of Ramucirumab With Best Supportive Care in Patients With Gastric Cancer and Adenocarcinoma

Conditions: Gastric Cancer; Adenocarcinoma
Interventions: Biological: ramucirumab; Other: Placebo; Other: Best Supportive Care
Sponsor: ImClone LLC
Recruiting - verified August 2010
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsor: NovoCure Ltd.
Recruiting - verified August 2010
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified August 2010
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2010
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified August 2010
Eslicarbazepine Acetate Monotherapy Long Term Study

Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified April 2010
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified May 2010
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

Condition: Parkinson Disease
Interventions: Drug: isradipine cr; Drug: placebo/ sugar pill
Sponsors: The Parkinson Study Group; Michael J. Fox Foundation for Parkinson's Research; Northwestern University Dixon Fund
Recruiting - verified August 2010
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2010
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)

Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention:
Sponsor: Scripps Health
Recruiting - verified August 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Ventavis® Registry Protocol

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified August 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsor: Bayer
Recruiting - verified August 2010
Safety Follow-Up to HP 802-247-09-015

Conditions: Venous Leg Ulcer; Venous Stasis Ulcer
Intervention:
Sponsor: Healthpoint
Recruiting - verified August 2010
Citalopram for Agitation in Alzheimer's Disease

Conditions: Alzheimer's Disease; Agitation
Interventions: Drug: citalopram; Drug: placebo
Sponsors: Johns Hopkins University; National Institute on Aging (NIA); National Institute of Mental Health (NIMH)
Recruiting - verified September 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 300/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 400/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified August 2010
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Functional MRI Before and After Treatment for Depression

Conditions: Depression; Mood Disorders; Depressive Disorder
Intervention: Drug: Citalopram
Sponsor: Stanford University
Recruiting - verified August 2010
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke; Stroke; Brain Infarction
Interventions: Drug: Eptifibatide; Drug: rt-PA
Sponsors: University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Condition: Locally Advanced or Metastatic Pancreatic Cancer
Intervention: Drug: FG-3019
Sponsor: FibroGen
Recruiting - verified August 2010
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Condition: Crohn's Disease
Interventions: Drug: certolizumab pegol; Drug: certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Study Evaluating a Planned Transition From Tacrolimus to Sirolimus in Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsor: Wyeth
Recruiting - verified August 2010
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified September 2010
Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia

Conditions: Leukemia; Leukemia Acute Myeloid Leukemia (AML)
Interventions: Drug: lenalidomide; Drug: Azacitidine
Sponsors: Stanford University; Celgene Corporation
Recruiting - verified August 2010
Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

Condition: Non-Cystic Fibrosis Bronchiectasis
Interventions: Drug: Ciprofloxacin for Inhalation; Drug: Ciprofloxacin for Inhalation; Drug: Placebo
Sponsor: Aradigm Corporation
Recruiting - verified August 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified August 2010
Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cixutumumab; Drug: Hedgehog antagonist GDC-0449; Drug: cisplatin; Drug: etoposide phosphate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
High-Dose Fluconazole for the Treatment of CM in HIV-infected People

Conditions: Cryptococcal Meningitis; HIV Infections
Interventions: Drug: Fluconazole; Drug: Amphotericin B
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: RO5313534; Drug: RO5313534; Drug: RO5313534; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2010
A Study of Patients With Relapsing Remitting Multiple Sclerosis

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010

Clinical Trials California - Join Reasearch Studies and clinical trials in California - Database

Clinical Trials California - Join Reasearch Studies and clinical trials in California

Paid Clinical Trials and Focus Groups by Location